Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome

Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome

US Patent 12156903 · Granted Dec 3, 2024

Estimated economic value: $124,886,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Methods of treating or preventing a cardiovascular system complication of sickle2025
Methods of prophylactic treatment using recombinant VWF (rVWF)2024
Treatment of gastrointestinal bleeding in patients with severe von Willebrand di2024
Methods of administering high concentrations of nitric oxide2023
Treatment of gastrointestinal bleeding in patients with severe von Willebrand di2022
Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive cris2021
Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive cris2021
Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive cris2021
Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive cris2021
Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive cris2021
Treatment of gastrointestinal bleeding in patients with severe von Willebrand di2021
Treatment of gastrointestinal bleeding in patients with severe von Willebrand di2020